oppn parties Covid Vaccines: Patent Waiver Will Ensure Fast And Easy Availability At Reasonable Cost

News Snippets

  • India's sovereign green bonds were oversubscribed four times as the RBI received 266 bids worth Rs 32892cr agaisnt the target of Rs 8000cr
  • Google tweaks its Android and India app store policy to allow manufacturers and users to choose certain things instead of compulsorily using Google apps after the CCI order and fine for unfairly dominating the market
  • Former US secretary of state calls former Indian external affairs minister Sushma Swaraj a "goofback" and a "hinterland political hack". MEA S Jaishankar slams him
  • Jamia screening of BBC documentary on Gujarat riots cancelled after the university was turned into a fortress and later 13 students were detained by the police
  • Supreme Court grants conditional interim bail for eight weeks to Lakhimpur Kheri accused Ashish Mishra. The bail can be further extended based on his conduct. He was asked to stay outside Delhi-NCR and UP and surrender his passport
  • After the JNU administration tried to thwart the students from screening the BBC documentary on the Gujarat riots and PM Modi, now students of Presidency and Jadavpur universities in Kolkata have decided to screen it 5 times next week
  • While a US research frim Hindenburg says its analysis found the Adani group overleveraged and claimed that its bubble will burst very soon and that sent the price of group companies crashing (Adani companies lost a combined Rs 55000cr), Adani group said the report was 'baseless' and 'malicious'
  • This time Enforcement Directorate arrests TMC spokesperson Saket Gokhale under PMLA for money laundering
  • Padma awards announced on Republic Day: Mulayam Singh Yadav, architect Balkrishna Doshi and ORS pioneer Dilip Mahalanobis get Padma Bibhushan posthumously, Padma Bhushan ius awarded to Kumar Mangalam Birla and 8 others and 91 get Padma Shri
  • Stocks fall big time on Wednesday on F&O expiry, finalncial and banks take big hit: Sensex tumbles 773 points to 60205 and Nifty 226 points to 17892 even as the market volatility meter shoots up by 8.51%
  • World Cup hockey: Germany stun England 4-3 to reach semifinals; Netherlands beat Korea 5-1 to enter last four
  • Australian Open: Sania Mirza and Rohan Bopanna reach the finals
  • Suryakumar Yadav is named ICC Cricketer of the Year 2022 and Renuka Singh gets the ICC Emerging Cricketer of the Year 2022 award
  • BCCI gets a whopping Rs 4670cr in the auctions for the 5 teams in WIPL or as it will be known now, WPL. Adani Sportline gets Ahmedabad for Rs 1289cr while Mumbai Indians get Mumbai for 913cr
  • Calcutta HC overturns the hookah bar ban in Kolkata by saying that it is not an illegal trade
India Commentary Wishes A Happy Republic Day To All Its Readers /////// India Commentary Wishes A Happy Basant Panchami And Saraswati Puja To All Its Readers
oppn parties
Covid Vaccines: Patent Waiver Will Ensure Fast And Easy Availability At Reasonable Cost

By Sunil Garodia
First publised on 2021-05-08 05:29:04

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

The positive response of the world community (except the European Union, more particularly Germany), especially the US, for temporary patent waiver on Covid vaccines, is laudable. There is no doubt that billions of dollars are spent in research for developing new medicines or drugs and this is especially true of Covid-related vaccines and drugs. But given the urgency and importance of these vaccines, the research for most of them was funded by governments and public money. Hence, given the nature of the pandemic there must be temporary patent waiver on these vaccines to make them available to everyone and at a cheaper cost.

Research-based and patented drugs are costly because the companies that make them need to recover more than the billions they spent in developing them to fund further research. If they are not normally allowed to price their products accordingly to recover costs and make 'super' profits for funding further research, there will be no incentive to undertake research and develop new medicines and vaccines. But when such research is funded by public money, the patent must ideally rest with the public, as is the case of Covaxin developed by Bharat Biotech in association with ICMR and funded by the government. In such cases, and when the entire humanity is threatened, patents must be foregone to allow all those who have the manufacturing facility to make the vaccines.

India must allow all manufacturers, both public sector units and private producers, who are capable of producing vaccines to start production of Covaxin under the compulsory licensing norms, for both SI and Bharat Biotech have made it clear that it will take time for them to ramp up their manufacturing facilities. Hence, all idle capacity in the country must now be utilized. Later, when temporary patent waiver happens, these manufacturers can make all vaccines. That would ensure easy and cheaper availability of all vaccines and India will also be able to fulfill it humanitarian obligations to other nations. For, as UN Secretary-General Antonio Guterres has pointed out, "No one is safe till all are safe". All nations have to ensure that every eligible person in the world is fully vaccinated as early as possible.